Finance

Lists
4568:TYO
Daiichi Sankyo Co Ltd
2 716,00 JP¥
+0,26%
(+7,00) 1D
5-окт., 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4568...
Open
2 699 JP¥
High
2 739 JP¥
Low
2 691 JP¥
Mkt. cap
5,06 трлн
Avg. vol.
6,03 млн
Volume
4,80 млн
Dividend
2,87%
Quarterly dividend
19 JP¥
P/E ratio
20,57
52-wk high
4 178 JP¥
52-wk low
2 390 JP¥
EPS
132 JP¥
Shares outstanding
647,77 млн
No. of employees
20 миң
Open
2 699 JP¥
High
2 739 JP¥
Low
2 691 JP¥
Mkt. cap
5,06 трлн
Avg. vol.
6,03 млн
Volume
4,80 млн
Dividend
2,87%
Quarterly dividend
19 JP¥
P/E ratio
20,57
52-wk high
4 178 JP¥
52-wk low
2 390 JP¥
EPS
132 JP¥
Shares outstanding
647,77 млн
No. of employees
20 миң
News stories
From web sources and news partners
Profile
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent. Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey. Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries. Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
About Daiichi Sankyo Co Ltd
CEOHiroyuki Okuzawa
Employees20,2 миң
Founded2005-ж., 28-сен.
HeadquartersChuo City, Tokyo, Япония
Sector-
Last report
2026-ж., 31-июл.
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
574,74 млд / 533,58 млд
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
500,76 млд
558,11 млд
589,59 млд
574,74 млд
Cost of goods sold
155,98 млд
118,28 млд
302,44 млд
124,29 млд
Cost of revenue
155,98 млд
118,28 млд
302,44 млд
124,29 млд
Research and development expenses
111,72 млд
122,11 млд
126,23 млд
115,46 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
189,08 млд
228,23 млд
154,06 млд
249,96 млд
Operating expense
297,25 млд
350,29 млд
279,38 млд
365,35 млд
Total operating expenses
453,23 млд
468,57 млд
581,82 млд
489,64 млд
Operating income
47,52 млд
89,54 млд
7,77 млд
85,10 млд
Other non operating income
-
-
6,22 млд
-2,00 млн
EBT including unusual items
57,78 млд
106,73 млд
22,44 млд
91,34 млд
EBT excluding unusual items
57,78 млд
106,73 млд
7,84 млд
91,34 млд
Income tax expense
12,46 млд
20,10 млд
-39,84 млд
22,70 млд
Effective tax rate
21,57%
18,83%
-177,52%
24,86%
Other operating expenses
-3,56 млд
-49,00 млн
-908,00 млн
-69,00 млн
Net income
45,31 млд
86,63 млд
62,28 млд
68,64 млд
Net profit margin
9,05%
15,52%
10,56%
11,94%
Earnings per share
-
-
-
-
Interest and investment income
10,68 млд
19,08 млд
377,00 млн
9,74 млд
Interest expense
-834,00 млн
-2,16 млд
-18,91 млд
-3,23 млд
Net interest expenses
9,84 млд
16,91 млд
-18,53 млд
6,51 млд
Depreciation and amortization charges
-
-
-
-
EBITDA
66,41 млд
109,18 млд
28,89 млд
106,58 млд
Gain or loss from assets sale
1,75 млд
573,00 млн
8,50 млд
180,00 млн
AI content may include mistakes. Learn more
Google колдонмолору